<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510884</url>
  </required_header>
  <id_info>
    <org_study_id>EFC14643</org_study_id>
    <secondary_id>2017-001903-60</secondary_id>
    <secondary_id>U1111-1193-0721</secondary_id>
    <nct_id>NCT03510884</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of alirocumab administered every 2 weeks (Q2W) versus placebo after
      24 weeks of double-blind (DB) treatment on low-density lipoprotein cholesterol (LDL-C) levels
      in patients with heterozygous familial hypercholesterolemia (heFH) 8 to 17 years of age on
      optimal stable daily dose of statin therapy Â± other lipid modifying therapies (LMTs) or a
      stable dose of non-statin LMTs in case of intolerance to statins.

      Secondary Objectives:

        -  To evaluate the efficacy of alirocumab versus placebo on low-density lipoprotein
           cholesterol (LDL-C) levels.

        -  To evaluate the effects of alirocumab versus placebo on other lipid parameters.

        -  To evaluate the safety and tolerability of alirocumab in comparison with placebo.

        -  To evaluate the efficacy, safety, and tolerability of alirocumab after open label
           treatment.

        -  To evaluate the development of anti-alirocumab antibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration is approximately up to 110 weeks (run-in period [if needed]: up to 4 weeks
      [+2 days], screening period: up to 2 weeks [+5 days], double-blind treatment period: 24
      weeks, open label treatment period: 80 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 14, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Percent change in LDL-C from baseline to Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in LDL-C</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Percent change in LDL-C from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo B</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Percent change in Apo B from baseline to Week 12 and to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in non-high density lipoprotein cholesterol (non HDL-C)</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Percent change in non-HDL-C from baseline to Week 12 and to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Total-C</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Percent change in Total-C from baseline to Week 12 and to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with LDL-C level &lt;130 mg/dL (3.37 mmol/L)</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Proportion of patients with LDL-C level &lt; 130 mg/dL (3.37 mmol/L) at Week 12 and at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with LDL-C level &lt;110 mg/dL (2.84 mmol/L)</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Proportion of patients with LDL-C level &lt; 110 mg/dL (2.84 mmol/L) at Week 12 and at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Lp(a)</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Percent change in lipoprotein (a) from baseline to Week 12 and to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Percent change in HDL-C from baseline to Week 12 and to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in TG</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Percent change in fasting triglycerides (TG) from baseline to Week 12 and to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo A-1</measure>
    <time_frame>From baseline to Week 12 and to Week 24</time_frame>
    <description>Percent change in apolipoprotein A1 (Apo A-1) from baseline to Week 12 and to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to Week 104</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cogstate battery test</measure>
    <time_frame>At Day 1, Weeks 24, 68, and 104</time_frame>
    <description>The Cogstate battery test will assess maturing cognition across a broad number of key developmental functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner stage</measure>
    <time_frame>At Weeks 24, 44, 68, and 104</time_frame>
    <description>The Tanner stages will be measured to assess stages of pubertal development -</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>Alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab (one of 2 doses, depending on body weight) will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alirocumab Placebo will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab SAR236553 (REGN727)</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous injection</description>
    <arm_group_label>Alirocumab</arm_group_label>
    <other_name>Praluent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin</intervention_name>
    <description>Pharmaceutical form:Capsule Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholestyramine</intervention_name>
    <description>Pharmaceutical form:oral suspension Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinic acid</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>Pharmaceutical form:capsule Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Children and adolescent male and female patients aged 8 to 17 years at the time of
             signed informed consent.

          -  Patients with diagnosis of heterozygous familial hypercholesterolemia (heFH) through
             genotyping or clinical criteria.

          -  Patients treated with optimal dose of statin +/- other LMT(s) or non-statin LMT(s) if
             statin intolerant at stable dose for at least 4 weeks prior to screening lipid
             sampling.

          -  Patients with calculated LDL-C greater than or equal to 130 mg/dL (â¥3.37 mmol/L) at
             the screening visit except for patients who have previously participated in the
             DFI14223 study.

          -  A signed informed consent indicating parental permission with or without patient
             assent.

        Exclusion criteria:

          -  Patient with body weight less than 25 kg.

          -  Patients aged of 8 to 9 years not at Tanner stage 1 and patients aged of 10 to 17
             years not at least at Tanner stage 2 in their development.

          -  Patients with secondary hyperlipidemia.

          -  Diagnosis of homozygous familial hypercholesterolemia.

          -  Patient who has received lipid apheresis treatment within 2 months prior to the
             screening period, or has plans to receive it during the study.

          -  Patients with uncontrolled type 1 or type 2 diabetes mellitus.

          -  Patients with known uncontrolled thyroid disease.

          -  Patients with uncontrolled hypertension.

          -  Fasting triglycerides &gt;350 mg/dL (3.95 mmol/L).

          -  Severe renal impairment (ie, estimated glomerular filtration rate [eGFR] &lt;30
             mL/min/1.73 m^2.

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2 x upper limit of
             normal (ULN).

          -  Creatinine phosphokinase (CPK) &gt;3 x ULN.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
    <mesh_term>Cholestyramine Resin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

